|
|
 |
|
Viewing report
|
|
|
|
Emerging Therapeutics in the U.S. Non-small Cell Lung Cancer Markets
Frost & Sullivan, Oct 2004
Targeted Therapies Struggling to Gain Acceptance as First Line Treatments
Once touted as the next big thing in curing cancer, targeted therapies have fallen drastically short of the expectations of the healthcare community regarding the ability to treat non-small cell lung cancer (NSCLC). In fact, targeted therapies such as Iressa and Tarceva have failed to gain approval as first line therapies for NSCLC and are instead preferred as second- and third-line treatment options. Although targeted therapies have not shown the results required to replace chemotherapy completely in NSCLC patients, there is hope among oncologists that these are likely to be successful as adjuvant treatments post-surgery or in combination with chemotherapy. However, in the long run, targeted therapies seeking to achieve blockbuster status need to move from their position as second- or third-line therapies towards standard of care treatment for NSCLC.
This Frost & Sullivan research evaluates the key developments in the NSCLC therapeutics market and analyzes the key drivers and challenges affecting current and future growth. It also provides in-depth pipeline and product analysis for cytotoxic and targeted therapies.
Absence of Chemotherapy in NSCLC Treatment Presents Opportunities for Targeted Therapies
While chemotherapy is the treatment of choice for first and second line NSCLC, targeted therapies are expected to make an impact on patients too sick for chemotherapy or unwilling to take chemotherapy. Late stage NSCLC patients that are unlikely to derive the full benefits of chemotherapy might also consider targeted therapies to improve their quality of life if not extend it, says the analyst.
There could be various other grounds on which a patient might be forced to skip or voluntarily refuse chemotherapy. For instance, patients over the age of 70 or with poor health may be advised against the chemotherapy treatment. Other patients might refuse treatment since the intense side effects outweigh the clinical benefits of chemotherapy. Annually, approximately 20,000 patients do not receive chemotherapy and, though this is a relatively small population, it is still a large enough group to create significant revenue increase for other treatment options.
Equipped with Added Advantages, Targeted Therapies Compete with Chemotherapy
Although chemotherapy reigns supreme as the first line of treatment for NSCLC, targeted therapies are not far behind with their ability to offer easier administration (in the form of pills and injections) and a lower side-effect profile compared to chemotherapy agents. Armed with such benefits, if targeted therapies succeed in gaining approval as a first line of treatment for NSCLC, it can access a population size of 60,000 to 70,000 patients. Combined with the high cost of targeted therapies, such a large population size is expected to drive this market forward, explains the analyst.
Customers who bought this item also bought
Chemotherapy Market Insights, 2006-2016: A Critical Analysis of Cancer Research, Treatments, Pipelines, and Commercial Opportunities
Non-Small Cell Lung Cancer - Avastin to Lead the Market
Treatment Algorithms 2001: Lung Cancer
Drugs of Tomorrow 2001: Lung Cancer
Cancer Therapeutics 2006: Market Dynamics and R&D Trends
New Cancer Therapeutics: An Analysis Of Current And Emerging Markets
Ovarian Cancer Therapeutics - Global Strategic Business Report
25+ Business Development and Innovation Opportunities in Cancer Medicine - 2001
|
|
|
|
